Efficacy of NovoSeven® in Bleeding Prophylaxis in Hemophilia
| Status: | Completed |
|---|---|
| Conditions: | Hematology, Hematology |
| Therapuetic Areas: | Hematology |
| Healthy: | No |
| Age Range: | 2 - Any |
| Updated: | 1/13/2017 |
| Start Date: | March 2004 |
| End Date: | November 2005 |
Exploratory, Multi-centre, Randomised, Double-blind, Uncontrolled Trial Evaluating the Efficacy of Activated Recombinant Factor VII (rFVIIa/NovoSeven®) in Secondary Bleeding Prophylaxis in Congenital Haemophilia A or B Patients With Inhibitors
This trial is conducted in Africa, Asia, Europe, South America, and the United States of
America (USA).
The purpose of this study is to evaluate the effectiveness of secondary prophylactic
treatment with NovoSeven® in haemophilia A and B patients with inhibitors.
America (USA).
The purpose of this study is to evaluate the effectiveness of secondary prophylactic
treatment with NovoSeven® in haemophilia A and B patients with inhibitors.
Inclusion Criteria:
- Diagnosis of congenital haemophilia A or B with inhibitors development against FVIII
or FIX, respectively
Exclusion Criteria:
- Prophylactic administration of any haemostatic drug within 3 last months prior to
entering the trial.
We found this trial at
13
sites
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials